Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized open-label trial of Ancilla Domini KDS agonists 234-A and 233-B in kidney disease
PACTR202410587273157Phase 1Not yet recruiting
- Sponsor
- Ancilla Domini International Researchers
- Start
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in chronic kidney disease (CKD) (2 arms), sponsored by Ancilla Domini International Researchers. Planned start Nov 2024; status: not yet recruiting.
02
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on PACTR202410587273157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410587273157.